Vanguard Asset Management
MLYS icon

Vanguard Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Vanguard Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
39,187
+9,934
+34% +$273K ﹤0.01% 1850
2026
Q1 		$792K Buy
+29,253
New +$858K ﹤0.01% 1891

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Asset Management's MLYS Position: Q2 2026 in Review

Vanguard Asset Management increased its Mineralys Therapeutics (MLYS) stake by 34% in Q2 2026, buying an estimated $273K and bringing the position to 39,187 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1850.

Vanguard Asset Management first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Vanguard Asset Management held 39,187 shares of Mineralys Therapeutics worth $1.06M as of Q2 2026.
  • Vanguard Asset Management bought 9,934 Mineralys Therapeutics shares in Q2 2026, an estimated $273K.
  • Mineralys Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1850 holding.
  • Vanguard Asset Management first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 201 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.